CRSP CRISPR Therapeutics AG

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRSP

Price (delayed)

$55.65

Market cap

$4.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.94

Enterprise value

$4.3B

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that ...

Highlights
The revenue has surged by 118% since the previous quarter
The company's gross profit has surged by 118% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://crisprtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CRSP
Market
Shares outstanding
80.28M
Market cap
$4.47B
Enterprise value
$4.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
11.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.6
Earnings
Revenue
$371.21M
EBIT
-$150.72M
EBITDA
-$130.89M
Free cash flow
-$269.85M
Per share
EPS
-$1.94
Free cash flow per share
-$3.41
Book value per share
$23.7
Revenue per share
$4.69
TBVPS
$28.14
Balance sheet
Total assets
$2.23B
Total liabilities
$346.77M
Debt
$238.63M
Equity
$1.88B
Working capital
$1.8B
Liquidity
Debt to equity
0.13
Current ratio
17.54
Quick ratio
17.51
Net debt/EBITDA
1.24
Margins
EBITDA margin
-35.3%
Gross margin
100%
Net margin
-41.4%
Operating margin
-60%
Efficiency
Return on assets
-7%
Return on equity
-8.4%
Return on invested capital
-8.1%
Return on capital employed
-7.1%
Return on sales
-40.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
-1.35%
1 week
0.16%
1 month
-22.29%
1 year
8.95%
YTD
-11.1%
QTD
-18.35%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$371.21M
Gross profit
$371.21M
Operating income
-$222.54M
Net income
-$153.61M
Gross margin
100%
Net margin
-41.4%
The revenue has surged by 118% since the previous quarter
The company's gross profit has surged by 118% QoQ
The operating margin has surged by 100% year-on-year and by 76% since the previous quarter
The net margin has surged by 100% year-on-year and by 80% since the previous quarter

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
CRSP P/E details
P/E
N/A
P/B
2.35
P/S
11.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.6
The EPS has surged by 77% year-on-year and by 57% since the previous quarter
The price to book (P/B) is 33% lower than the 5-year quarterly average of 3.5 but 2.2% higher than the last 4 quarters average of 2.3
The equity has increased by 9% QoQ
The revenue has surged by 118% since the previous quarter
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 1463.6 and 51% lower than the last 4 quarters average of 24.0

Efficiency

How efficient is CRISPR Therapeutics AG business performance
The return on sales has surged by 100% year-on-year and by 81% since the previous quarter
The ROIC has soared by 75% YoY and by 57% QoQ
The company's return on assets has surged by 74% YoY and by 57% QoQ
The ROE has soared by 74% YoY and by 57% from the previous quarter

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio is up by 16% YoY and by 11% QoQ
CRISPR Therapeutics AG's current ratio has increased by 15% YoY and by 11% from the previous quarter
The debt is 87% smaller than the equity
The equity has increased by 9% QoQ
CRSP's debt to equity is down by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.